Full-Time

Head of Regulatory Affairs

Cell Therapy Immunology

Posted on 5/2/2025

Deadline 5/31/25
AstraZeneca

AstraZeneca

10,001+ employees

Develops and commercializes prescription medicines

Compensation Overview

$266.6k - $399.9k/yr

+ Short-term incentive bonus + Equity-based long-term incentive program

Expert

Boston, MA, USA

In-person working requires a minimum of three days per week from the office.

Category
Risk & Compliance
Legal & Compliance
Biology & Biotech
Requirements
  • Bachelor’s degree in life sciences and/or science related field and/or other appropriate knowledge/experience.
  • More than 10 years drug development experience
  • Broad experience of the therapeutic area, with specific cell therapy immunology regulatory sciences expertise and immune-mediated diseases.
  • Experience in global regulatory strategy and submissions that have progressed through to registration
  • Must have significant experience in leading major Health Authority interactions
  • Broad background of experience working in pharmaceutical/medical industry and prior experience in several areas within regulatory affairs, e.g. Global, European, International, Marketing Company or experience at a health authority.
  • Experience in managing people in a matrixed organizational structure
Responsibilities
  • Provide oversight, partner with, and mentor RADs and SrRADs to produce strategies for a product/group of products in the Immunology Cell Therapy TA that are consistent with the disease area and portfolio strategy.
  • Leads discussions in both internal and external forums, providing expertise in regulatory knowledge of disease area.
  • Influences and drives regulatory strategies and recommendations at all stages of development, in early and late development, and for established brands on regulatory components of development specific to cell and gene therapies as well as other tools such as novel endpoints/biomarkers, novel study designs, and digital applications.
  • Effectively represent the Regulatory function in senior level interactions at internal governance technical review committees e.g. Development Review Committee (DRC/eDRC), Early Development Review Board, Global Medical Affairs (GMA) Review Committees.
  • Works in collaboration with regional policy and intelligence groups to critically analyse the assessment of emerging science, data and changes in the regulatory environment.
  • Defines and drives disease area global regulatory policies and priorities within the TA.
Desired Qualifications
  • Advanced degree in a scientific field (e.g. MSc, PhD, PharmD, MD)

AstraZeneca develops and sells prescription medicines, focusing on three main areas: Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. The company conducts extensive research and clinical trials to create new treatments, ensuring they meet regulatory standards before reaching the market. AstraZeneca stands out from competitors through its collaborative approach, including partnerships and its Open Innovation program, which accelerates drug discovery. The company's goal is to improve healthcare by providing effective treatments for serious diseases globally.

Company Size

10,001+

Company Stage

IPO

Headquarters

Cambridge, United Kingdom

Founded

1913

Simplify Jobs

Simplify's Take

What believers are saying

  • AstraZeneca's AI partnerships enhance drug discovery and protein folding efficiency.
  • The new Rockville cell therapy facility represents significant investment in future growth.
  • Strategic partnerships, like with Danaher, advance precision medicine diagnostics.

What critics are saying

  • Integration challenges may arise from AstraZeneca's stake in Niox Group.
  • Geopolitical risks could impact the CSPC partnership due to China's regulatory environment.
  • Ethical scrutiny may delay AI solutions like MapDiff in drug discovery.

What makes AstraZeneca unique

  • AstraZeneca focuses on three main therapy areas: Oncology, Cardiovascular, and Respiratory.
  • The company invests heavily in R&D to create innovative prescription medicines.
  • AstraZeneca's A.Catalyst Network fosters global collaboration and innovation in healthcare.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Paid Holidays

Flexible Work Hours

Company News

Devdiscourse
Jun 18th, 2025
AstraZeneca's Stake in Niox Group: A Strategic Partnership | Headlines

AstraZeneca PLC has acquired a significant stake of 15.86% in Niox Group PLC, according to a recent company filing. This move signals strategic collaboration opportunities between the two companies, potentially aligning their interests in the pharmaceutical industry and expanding their influence in the sector.

InfBusiness
Jun 17th, 2025
Scientists present AI solution for protein folding

Scientists from the University of Sheffield, in partnership with AstraZeneca, have developed an artificial intelligence system called MapDiff, which allows for more efficient creation of proteins with a giventhree-dimensional structure and biological functions.

Cision
Jun 13th, 2025
Astrazeneca Enters Into Collaboration With Cspc

AstraZeneca enters into collaboration with CSPC

Cision
Jun 6th, 2025
Fixed-Duration Calquence Approved In Eu For 1L Cll

Fixed-duration Calquence approved in EU for 1L CLL

Business Weekly
Jun 5th, 2025
Sortera Bio secures £7.5m pre-seed funding

Sortera Bio, a Cambridge biotech, secured a £7.5m pre-seed round led by Cambridge Innovation Capital, with AstraZeneca and BioNTech participating. The funding will enhance Sortera's Deep Screening platform, which uses AI for drug discovery. Co-founded by Dr. Ben Porebski and Dr. Philipp Holliger, Sortera aims to deliver precision biologics. The technology was developed at the MRC Laboratory of Molecular Biology with AstraZeneca's support.

INACTIVE